Thursday, January 30, 2014

MPNRF blood cancer researcher Robert Kralovics talks about momentous dis...

1 comment:

  1. Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, Pacritinib

    ReplyDelete